5 March 2024
(“Avacta” or “the Group” or “the Company”)
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the
Presentation details
Title: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Session Title: First-in-Human Phase I Clinical Trials 2
Session Date and Time: Tuesday
Location:
Abstract Presentation Number: CT188
First Author:
-Ends-
For further information from
Tel: +44 (0) 1904 21 7070 www.avacta.com | |
Tel: +44 (0) 207 710 7600 www.stifel.com | |
Peel Hunt (Joint Broker) | Tel: +44 (0) 207 418 8900 www.peelhunt.com |
ICR Consilium (Media and IR) | avacta@consilium-comms.com |
About AVA6000
AVA6000, Avacta Therapeutics’ lead oncology program, is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by fibroblast activation protein (FAP) in the tumor microenvironment (TME). FAP is selectively overexpressed in many solid tumors. The peptide moiety (pre|CISIONTM) prevents cellular entry of doxorubicin unless cleaved by FAP, thus enabling targeted delivery of doxorubicin directly to the TME.
About
The pre|CISION™ platform modifies chemotherapy to be activated only in the tumour tissue, reducing systemic exposure and toxicity. This is achieved by harnessing an enzyme called FAP which is highly upregulated in most solid tumours compared with healthy tissues, turning chemotherapy into a “precision medicine”. The lead pre|CISION™ programme, AVA6000 a tumour activated form of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity.
Affimer® is a novel biologic platform which has significant technical and commercial advantages compared with antibodies and is used both to develop advanced immunotherapies and to improve the performance of immunodiagnostics.
With a balanced business and capital allocation model: a high-value oncology pipeline supported by a revenue generating, fast-growing diagnostics business,
To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/
Source:
2024 GlobeNewswire, Inc., source